한빛사논문
- 조회419
Hyoin Shin 1#, Heeje Shin 1#, Masoud Rahmati 2#, Ai Koyanagi 3,4, Louis Jacob 3,5, Lee Smith 6, Sang Youl Rhee 7,8, Rosie Kwon 7, Min Seo Kim 9, Sunyoung Kim 10, Jae Il Shin 11*, Chanyang Min 7*, Wonyoung Cho 7*, Dong Keon Yon 7,12*
1Department of Medicine, Kyung Hee University College of Medicine, Seoul, South Korea.
2Department of Physical Education and Sport Sciences, Faculty of Literature and Human Sciences, Lorestan University, Khoramabad, Iran.
3Research and Development Unit, Parc Sanitari Sant Joan de Deu, CIBERSAM, ISCIII, Barcelona, Spain.
4Catalan Institution for Research and Advanced Studies (ICREA), Pg. Lluis Companys, Barcelona, Spain.
5Faculty of Medicine, University of Versailles Saint-Quentin-en-Yvelines, Montigny-le-Bretonneux, France.
6Centre for Health, Performance and Wellbeing, Anglia Ruskin University, Cambridge, UK.
7Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.
8Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, Korea.
9Medical and Population Genetics and Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
10Department of Family Medicine, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.
11Department of Pediatrics, Yonsei University College of Medicine, Seoul, South Korea.
12Department of Pediatrics, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.
#The authors were contributed equally
*CORRESPONDING AUTHORS : Jae Il Shin, Chanyang Min, Wonyoung Cho, Dong Keon Yon
Abstract
Introduction: Currently, many cases of mpox patients living with the human immunodeficiency virus (HIV) have been reported. Immunocompromised mpox patients including those living with HIV are noted for an increased risk for severe symptoms; however, existing studies did not focus on the statistical comparison of mpox outcomes associated with HIV. Thus, we conducted a systematic review and meta-analysis to evaluate and compare the clinical manifestations of mpox in people living with HIV (PLWH) and people without HIV.
Methods: In this systematic review and meta-analysis, PubMed/MEDLINE, Embase, and Google Scholar were searched up to March 7, 2023. A random effects model was used to calculate the pooled prevalence along with the 95% confidence intervals (CI), and the odds ratio and its corresponding 95% CIs were calculated to elucidate the significance of each clinical feature for mpox patients with and without HIV.
Results: In this study, we included 99 published papers with 2413 patients with mpox (median age, 35.5 years; PLWH n=1151) from 27 countries across six continents. The odds ratio of the mpox outcomes with PLWH in comparison to patients without HIV was found to be significant for skin rash (1.24, 95% CI: 1.01 to 1.53), proctitis (2.03, 95% CI: 1.36 to 3.04), cough (0.57, 95% CI: 0.33 to 0.98), and diarrhoea (3.85, 95% CI: 1.24 to 11.98). The odds ratio of mpox patients with HIV for historical infections of syphilis was 2.14 (95% CI: 1.38 to 3.32), compared to those without HIV.
Conclusions: This is the first international and comprehensive study that performed a systematic review and meta-analysis to statistically measure mpox manifestations according to HIV status. As clinical features related to mucosal contact were characteristically pronounced in PLWH, our systematic review provides insight that the primary invasion site of infection strongly relates to the outcomes of mpox.
논문정보
- Research article
- 2023년 03월 (BRIC 등록일 2023-03-31)
- 국내(교신)+국외 연구진
- 의약학 > 응용의학
댓글 작성 로그인
팝업 닫기관련 링크
관련분야 연구자보기
관련분야 논문보기
